Single-cell and spatial multi-omic profiling maps the genetic and transcriptional changes from normal keratinocytes through actinic keratoses to invasive cutaneous squamous cell carcinoma
0:00Welcome to Base by Base, the papercast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. Okay, let's unpack this. Today, we're embarking on a deep dive into the genetic journey from a healthy, normal skin cell to cutaneous squoimacell carcinoma CSEC, which is, you know, globally the 2nd most common human cancer.
0:22But let's start with a really compelling biological question. If our skin is our single largest organ, and it is constantly bombarded by high energy UV radiation that just rips apart DNA, why doesn't literally everyone get cancer immediately?
0:36For years, the assumption was that the key cells involved, the keratinocytes, they must be heavily damaged as sort of genetic wrecked from decades of sun exposure. And that traditional assumption is, well, it's fundamentally challenged by the data in this new study.
0:49What the researchers found when they meticulously examined individual keratenocytes, the very cells that give rise to CSCC was pretty startling. They had a remarkably low background mutation burden. How low are we talking?
1:00We're talking about a median of only one. mutations per megabase or mutt memim. Yeah. And to put that in perspective, that's significantly lower than other cell types in the same skin biopsy, like Milanocytes, which average 3.91, and even dermal fibroblasts, which clocked in at one.
1:1792 met NB. So the default skin cell is actually incredibly resilient. That is genuinely surprising. It suggests the keratinocite has this robust defense system that is successfully dealing with all that UV assault.
1:30Yet despite this robustness. CSEC is a major clinical issue. I mean, it's responsible for an estimated 2500 to 15,000 deaths per year just in the U.S. Right. That a mortality rate on par with cancers we often think of as much deadlier, like melanoma and liver cancer.
1:44So the core mystery is this. How can a common and deadly cancer arise from cells that appear on the surface to be so genetically clean and resistant to damage? The answer, as this study reveals, lies in a catastrophic molecular switch that turns that resilience into a deadly, rapid malignancy.
2:02Today we celebrate the work of Bishel Tendakar, Delani Devendran, and the A Hunter Shane, along with their colleagues from the University of California, San Francisco, and other institutions, who have profoundly advanced our understanding of the genetic evolution of CSEC.
2:16So to set the stage, CSEC is undeniably common, it's the 2nd most common cancer globally, just behind basal cell carcinoma, but compared to other high mortality cancers, its specific evolutionary pathway, the step-by-step genetic roadmap to invasion, has been, well, poorly understood.
2:35We know where it starts, right? We do. It starts from keratinocytes and the epidermis, the outer layer of the skin. And this cancer development is often preceded by these pre-cancerous lesions called actinic keratoses or AKs.
2:45Those are the rough, scaly patches you see on chronically sunexposed areas. And previous sequencing efforts. They certainly gave us a snapshot of the finished product. We knew fully developed the SECs almost always harbor mutations that disrupt critical pathways, notably P53 signaling, the guardian of the genome, and not signaling.
3:06Right. And we also knew about later hits involving things like the MPK pathway, Swiss SNF, chromatin remodeling, and cell cycle control genes like CDK and 2A. But the central issue was the chronology. We just didn't know the critical sequencing, the order in which these mutations have to happen to transform a resilient normal skin cell into an invasive cancer.
3:27And that lack of clarity is a massive obstacle when you're trying to develop targeted prevention strategies or early biomarkers. You need to know which events are the ignition and which are the accelerator.
3:37So how do they solve that chronological problem? Well, the research team had to innovate their technical approach. Detecting somatic mutations in tiny individual cells with high accuracies notoriously difficult.
3:48So they adapted this complex workflow to finally achieve true single cell resolution. What was the key innovation? The key was something they called clonal expansion. So instead of trying to sequence one tiny keratinocite with very little DNA, which is hard to do accurately.
4:03Exactly. They 1st took that single cell X Viva out of the body and grew it into a small colony of about 200 daughter cells. So they essentially made a high quality photocopy of the original cells DNA. Precisely.
4:16This amplification process preserved the cell's initial mutation status, but gave them enough high quality genetic material to be reliably analyzed. This material was then subjected to multi-omic profiling.
4:29Meaning they looked at both the DNA and the RNA. The code itself and the instruction output. That clonal expansion technique sounds transformative. It guarantees they're getting reliable data from the very earliest stages.
4:41It does. And they coupled this with a multi-layered approach to study the entire progression. First, they profiled normal sales karatinocytes, melanocytes, and fiber blasts, from 22 biopsies just to establish that crucial baseline of resilience we talked about.
4:56Okay, so that sets the baseline. Then to track the actual progression, they performed extremely deep sequencing. The paper says 380 fold coverage. Which is just a huge amount of depth. For context, standard clinical sequencing might use 30, maybe 50 fold coverage.
5:13So they could spot very rare or subtle mutations with high confidence. Exactly. They applied this to 16 cases of CSEC that were immediately adjacent to the precursor AK lesion so they could track their genetic relationships.
5:25And there was a 3rd layer, wasn't there? Something about location. Yes, and this is critical. To understand where within the tissue these changes were happening, they used spatial transcript atomics. Specifically the 10 X Visium platform.
5:38This lets you map gene expression changes and immune interactions with uh, geographical precision. It shows you which cells are turning on which genes in a specific area of the tumor. Incredible. Okay, so let's dive into the core findings, starting with that initial paradox.
5:52Yeah. The keratenocite mutator phenotype. Right. So we established that the healthy keratinocite baseline is incredibly low, that one. one form muddle a ban. The cell is highly resilient. There's always a but. There is.
6:06Within that overall resilient population, they found a small insidious group of cells. These keratinocytes harbored pathogenic mutations, specifically in those famous cancer genes, TP 53 or NOTCH1. And when those genes were mutated.
6:22Their mutation burdens didn't just double. They skyrocketed, they reached up to an astonishing 49.71 mutt membe. Wait, wait. If the median is one. 14 and some cells jump to almost 50, we are talking about a 40 fold increase in the rate of damage accumulation.
6:38Yes, it's a fundamentally different kind of cell. So what does that suggest? It suggests that the TP 53 or NOTCH1 mutations don't just give the cell a modest growth advantage, as people previously thought.
6:50Instead, they act as a genetic accelerator. They're breaking the cell's internal machinery. Got it. They're breaking the machinery responsible for DNA, damaged surveillance and repair. By functionally eliminating those safety checks like apoptosis or error correction, these initial mutations induce what's called a mutator phenotype.
7:06The cell goes from being this controlled defensive unit to a hyperaccumulating damaged sponge. That's a great way to put it. It just rapidly accepts DNA damage from continuous UV exposure. The cell becomes genetically unstable, and that instability is the true early engine of cancer.
7:22And they had proof for this idea, right? Something about the clone sizes. They did. The researchers noted that clones of keratinocytes carrying these pathogenic TP 53 or NOTCH1 mutations were not significantly larger than clones without them in normal skin.
7:37That's a key point. So the initial advantage isn't massive, uncontrolled cell division. No, it's the rate of mutation accumulation that makes them dangerous long before they ever form a visible lesion.
7:49Okay, so that's the 1st step. What about the progression from the precursor AKs to the actual CSECs? This is where they found another major surprise, specifically regarding adjacency. In 6 of the 16 cases they analyze, the CSCC and the neighboring AK were genetically unrelated clones.
8:06hold on. That's a critical finding for clinical practice Are you saying dermatologists could see an AK and a CSEC lesion right next to each other? And they could actually be 2 entirely different cancers that just happen to grow near one another.
8:19It happens. It confirms that the skin is a mosaic of independent, mutated clones. The proximity is often just a coincidence, a collision of 2 separate proliferations. So you can't rely on the visual boundary.
8:31You can't. It can be misleading regarding the true genetic lineage and the extent of the invasive tumor. Well, what about the cases that did show clear progression? For the 8 bona fide cases, The evolutionary pathway was beautifully defined.
8:44They identified the trunk mutations, the early events that define AK formation. The usual suspect. Usual suspects. TB 53, NOTCH genes, turt promoter, which grants cellular immortality by reactivating telomerays, and CDKN2A, which overrides normal cell cycle breaks.
9:00Okay, so that's the AK. What triggers the jump to invasive cancer? That's the late events residing on the phylogenetic branches. This required a new specific set of mutations, and these were enriched precisely at the point of invasive transition.
9:13And what were they? They involved mutations disrupting the SwessenF chromatin remodeling complex, like arid 2 and activation, and activating the RTKRES map PK signaling pathway, often through genes like CBL.
9:25So let me see if I can simplify that. The early events are like disabling the car's books, and giving it an everlasting fuel supply, that creates the AK. That's an excellent analogy. But the late events like disrupting Soisson F, that's like breaking the car's internal filing system, causing total transcriptional chaos.
9:44And then you hit the MAPK accelerator to full throttle, which leads to invasion. That's it. It shows that invasion is a two step process. You 1st need the genetic instability, and then you need to acquire these specific mutations that reorganize the cellular architecture and signaling like era to you in a maffe activation to allow the cells to break through tissue barriers.
10:06And the spatial transcriptomics help them see how this happened. It did. It revealed significant spatial heterogeneity. The cells weren't uniform. While they retained some differentiation markers, the highly aggressive, stem like signatures were restricted specifically to the invasive front of the CSCC.
10:22The very edge where the tumor meets healthy tissue. Precisely. And this spatial organization was critical for understanding immunivation. The tumor cells concentrated right at that leading edge, we're pumping out high levels of immune checkpoint leggins.
10:37The do not kill me signal. Do not kill me signals. Things like PVR, Nectin 2, and CD 274. And the immune system was obviously picking up on this. Absolutely. The immune cells, the lymphocytes that were physically situated right at that invasive front were expressing high levels of the corresponding immune checkpoint proteins like CTLA 4, IGS, and PDCD1.
10:59So the tumor is basically establishing a molecular truce with the immune system precisely when it's trying to invade. It can only succeed because it switches on its invisibility cloak right at that specific point.
11:09Exactly. This is proof that immune evasion is not some passive or generalized event. It's an active geographically engaged mechanism that is critical to the transition to invasive malignancy. So what does this all mean when we put the entire evolutionary timeline together?
11:24The study provides a complete map. UV damage selects for TP 53 or NOTCH1 mutations, which act as that genetic accelerator, turning the keratinocite into a mutator phenotype. That sets the stage. And what?
11:37Then the subsequent acquisition of key mutations like area 2 disruption and MEPK activation drives the final critical immune evasive shift from a precursor AK lesion to invasive CSCC. And this clarifies the clinical complexity we discussed.
11:53Because these initial high mutation rate cells are so widespread, the skin is just full of these independent clones. Right. And the proximity of an AK to a CSCC doesn't guarantee they're related, which means dermatologist might need molecular confirmation, not just a visual assessment to understand the true extent of a tumor.
12:10What about the implications for treatment? This seems huge. It is. We already know that CSEC responds very well to immune checkpoint inhibitors. Now we know that those highly mutated TP 53 mutant keratinocytes, the cells with the massive mutation burden are widespread in clinically normal looking skin.
12:26They're like ticking time bombs. So if these high risk cells are everywhere in sun-exposed skin, how do we find them? How do we get rid of them before they even start the process? That is the profoundly important clinical question this raises.
12:38Future studies should explore whether prophylactic immunotherapies could be used. You mean like low dose or topical versions of existing treatments? Potentially. To specifically target and eliminate these TP 53 mutant precancerous cells, if we can intervene at the mupater phenotype stage, we might be able to eliminate the risk of cancer before an AK even forms.
13:00The take-o message here seems crystal clear. The genetic transformation of skin cancer begins when initial mutations in TP 53 and NOTCH1 transform keratinocytes from resilient cells into mutational hyperaccumulators.
13:12And then the later emergence of Arity 2 and MPK pathway mutations initiates the immune evasive invasive transition to full CSCC. This incredibly detailed understanding of the evolutionary sequence provides promising new candidate biomarkers for diagnosis and prognosis, which leaves us with this final thought.
13:30What does this mean for preventing skin cancer in the future, if we can potentially target pre-cancer cells before they ever become visible lesions. This episode was based on an open access article under the CCBY 4.0 license.
13:44You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating. If you'd like to support our work, use the donation link in description.
13:57Now stay with us for an original track created, especially for this episode, and inspired by the article you've just heard about. Thanks for listening and join us next time as we explore more clients, base by base.
